Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: BMcV who wrote (1469)	11/22/1998 4:57:00 PM
From: Ed Ajootian	Read Replies (2) \| Respond to of 10280

Bruce, I believe your concerns are justified and I plan to trim my position prior to the first point where those assumptions about future drug sales will be put to the test. I believe that point is about a year or so away though. None of the financial models have projected much Xopenex sales for '99, and Nori won't get approved until '00. Here's some interesting link that mentions SEPR in a recent article about Prozac: chron.com Great to see this kind of article proliferate. This must be putting immense pressure on Lilly to sign on the bottom line! Also, there is a great article in this week's BusinessWeek, discussing patents, particularly biotech patents. Mentions SEPR there too, for a coupla paragraphs.